Increasing Funding Associated with Research and Development to Foster the Growth of the Global Glycosylated Peptide Market

The global glycosylated peptide market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The global market for the glycosylated peptide is growing due to the increasing prevalence of diabetes across the globe and the growing geriatric population along with unhealthy lifestyles will drive the market during the forecast period. Furthermore, significant growth in the biopharmaceutical industry and increasing R&D activities to develop more targeted glycosylated peptides further boost the growth of the market. 

Browse the full report description “Global Glycosylated Peptide Market Size, Share and Trends Analysis Report, By Type (Monoclonal Antibodies (MABs), Erythropoietin (EPO), and Others), By Application (Oncology, Blood Disorder, and Others), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/glycosylated-peptide-market 

Moreover, increasing investment by the pharmaceutical companies to increase the utilization of the glycosylated peptide products and mergers with other companies will further drive the global glycosylated peptide market. For instance, in February 2022, Biocon Biologics Ltd. a subsidiary of Biocon ltd. announced that the company has entered into a definitive agreement with its partner Viatris Inc. to acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to $3.335 billion, including cash up to $2.335 billion and compulsorily convertible preference shares in Biocon Biologics Ltd. valued at $1 billion.

However, the major challenge faced by the global glycosylated peptide market is the complexities of manufacturing and the high cost of the active pharmaceutical ingredient (API), which in turn in will restrain the growth of the market. Furthermore, low economic conditions and a lack of favorable insurance systems may also hinder the growth of the global glycosylated peptide market. Moreover, some major players in the market include Bachem Group, Biocon Ltd., Celltrion Healthcare Co. Ltd., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., among others.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Bachem Group, Biocon Ltd., Celltrion Healthcare Co. Ltd., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Glycosylated Peptide Market Report Segment

By Type

• Monoclonal Antibodies (MABS)
• Erythropoietin (EPO)
• Others

By Application

• Oncology
• Blood Disorder
• Others

Global Glycosylated Peptide Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/glycosylated-peptide-market